Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28
NCT ID: NCT00204594
Last Updated: 2013-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
1 participants
INTERVENTIONAL
2005-10-31
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens
NCT00204516
Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients
NCT00204607
LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery
NCT00295958
Immunotherapy of Stage III/IV Melanoma Patients
NCT00112242
Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery
NCT00025181
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Antibody
rM28
autologous PBMCs
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
rM28
autologous PBMCs
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* injectable soft tissue metastasis
* informed consent given
* Karnofsky \>= 70%
Exclusion Criteria
* systemic glucocorticoids
* brain metestasis
* other malignancies
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thomas Eigentler
Study Coordinator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Garbe Claus, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
Department of dermatology, university of tuebingen
Gundram Jung, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
University of Tuebingen, Dept. of Immunology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Tuebingen, Department of dermatology
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
rM28-001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.